KalVista Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell KALV and other ETFs, options, and stocks.

About KALV

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa.

CEO

Benjamin L. Palleiko

CEOBenjamin L. Palleiko

Employees

270

Employees270

Headquarters

Framingham, Massachusetts

HeadquartersFramingham, Massachusetts

Founded

2004

Founded2004

Employees

270

Employees270

KALV Key Statistics

Market cap

685.10M

Market cap685.10M

Price-Earnings ratio

-3.38

Price-Earnings ratio-3.38

Dividend yield

—

Dividend yield—

Average volume

1.41M

Average volume1.41M

High today

$13.93

High today$13.93

Low today

$13.44

Low today$13.44

Open price

$13.48

Open price$13.48

Volume

218.05K

Volume218.05K

52 Week high

$17.28

52 Week high$17.28

52 Week low

$7.30

52 Week low$7.30

KALV News

TipRanks 5d

Promising Launch of Ekterly Boosts KalVista Pharmaceuticals’ Market Potential

Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on KalVista Pharmaceuticals and keeping the price target at $27.00. Elevate Your Investing Stra...

TipRanks 6d

KalVista Pharmaceuticals Reports Strong Start for EKTERLY Launch

KalVista Pharmaceuticals, Inc. ( (KALV) ) has released its Q1 earnings. Here is a breakdown of the information KalVista Pharmaceuticals, Inc. presented to its i...

TipRanks 6d

KalVista Pharmaceuticals’ Earnings Call Highlights EKTERLY Success

KalVista Pharmaceuticals, Inc. ((KALV)) has held its Q1 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advant...

Analyst ratings

100%

of 10 ratings

Buy

100%

Hold

Sell

More KALV News

Seeking Alpha 6d

KalVista Pharmaceuticals GAAP EPS of -$1.12 misses by $0.17, revenue of $1.43M misses by $0.66M

Earnings News KalVista Pharmaceuticals GAAP EPS of -$1.12 misses by $0.17, revenue of $1.43M misses by $0.66M Sep. 11, 2025 7:03 AM ET KalVista Pharmaceuticals,...

People also own

Based on the portfolios of people who own KALV. This list is generated using Robinhood data, and it’s not a recommendation.